Across TCGA pan-cancer cohorts, RPL13P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RPL13P data layer.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RPL13P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL13P expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.
CESC, BRCA, and STAD are the cancer types where RPL13P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.